Windlas Biotech Q2 FY27: revenue up 18.7% to ₹264 Cr, net profit up 1.7% to ₹18 Cr
Results · Finvezto · 5 Nov 2026 · Windlas Biotech (WINDLAS)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 264 | +6.4% | +18.7% |
| Operating profit | 29 | +10.1% | +2.8% |
| Net profit | 18 | +2.8% | +1.7% |
| Operating margin | 11.1% | +0.4 pp | -1.7 pp |
| Net margin | 6.9% | -0.2 pp | -1.1 pp |
Key points
- Windlas Biotech Limited reported revenue from operations of Rs 264 crore for Q2 FY27, up 19% YoY from Rs 222 crore, with adjusted EBITDA rising 20% YoY to Rs 36 crore and adjusted PAT up 29% YoY to Rs 25 crore. NSE filing
- Generic Formulations CDMO vertical revenue grew 34% YoY to Rs 215 crore, while Plant-6 was commercialized in September 2026. NSE filing
- Revenue was ₹264 Cr, up 18.7% on a year earlier and up 6.4% on the quarter before. Finvezto data
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 10.5%, 10.6%, 10.8%, 11.1%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 15, 16, 18, 18.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.